Genomic Vision
Financial Information for the Third Quarter of 2023 - Seite 3
For further information, please visit www.genomicvision.com
Member of the CAC Mid & Small and CAC All-Tradable indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking
statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 28, 2023 under number D.23-0383, available
on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of convertible notes with warrants (OCABSA) with its Financing partner.
The shares resulting from the conversion or exercise of the aforementioned securities will, in general, be sold on the market, which could create downward pressure on the share price as well as a
dilution.
Shareholders could therefore suffer a loss of their invested capital due to a significant decrease in the value of the company's shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before making a decision to invest in the company's securities.
1 Unaudited figures
2 Indicative dates, subject to change.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20231114282835/en/
The Genomic Vision Stock at the time of publication of the news with a raise of 0,00 % to 0,002EUR on Lang & Schwarz stock exchange (06. November 2023, 08:48 Uhr).